BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;:CD006257. [PMID: 17054288 DOI: 10.1002/14651858.CD006257] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Hewitt J, Castilla Guerra L, Fernández-Moreno Mdel C, Sierra C. Diabetes and stroke prevention: a review. Stroke Res Treat 2012;2012:673187. [PMID: 23326760 DOI: 10.1155/2012/673187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
2 Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2018;11:CD008170. [PMID: 30480768 DOI: 10.1002/14651858.CD008170.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
3 Tocci G, Volpe M. End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. Drugs 2011;71:1003-17. [PMID: 21668039 DOI: 10.2165/11591350-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Ucero AC, Gonçalves S, Benito-Martin A, Santamaría B, Ramos AM, Berzal S, Ruiz-Ortega M, Egido J, Ortiz A. Obstructive renal injury: from fluid mechanics to molecular cell biology. Open Access J Urol 2010;2:41-55. [PMID: 24198613 DOI: 10.2147/rru.s6597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lusignan Sd, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, McGovern A, Harris K. Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int 2013;84:609-20. [PMID: 23536132 DOI: 10.1038/ki.2013.96] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
6 Major RW, Brown C, Shepherd D, Rogers S, Pickering W, Warwick GL, Barber S, Ashra NB, Morris T, Brunskill NJ. The Primary-Secondary Care Partnership to Improve Outcomes in Chronic Kidney Disease (PSP-CKD) Study: A Cluster Randomized Trial in Primary Care. J Am Soc Nephrol 2019;30:1261-70. [PMID: 31097609 DOI: 10.1681/ASN.2018101042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 2016;17:127. [PMID: 27609359 DOI: 10.1186/s12882-016-0337-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 13.6] [Reference Citation Analysis]
8 Mao W, Yang N, Zhang L, Li C, Wu Y, Ouyang W, Xu P, Zou C, Pei C, Shi W, Zhan J, Yang H, Chen H, Wang X, Tian Y, Yuan F, Sun W, Xiong G, Chen M, Guan J, Tang S, Zhang C, Liu Y, Deng Y, Lin Q, Lu F, Hong W, Yang A, Fang J, Rao J, Wang L, Bao K, Lin F, Xu Y, Lu Z, Su G, Zhang, Johnson DW, Zhao D, Hou H, Fu L, Guo X, Yang L, Qin X, Wen Z, Liu X. Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial. Front Pharmacol 2020;11:627185. [PMID: 33708125 DOI: 10.3389/fphar.2020.627185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang HH, Hung CC, Hwang DY, Kuo MC, Chiu YW, Chang JM, Tsai JC, Hwang SJ, Seifter JL, Chen HC. Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease. PLoS One 2013;8:e67140. [PMID: 23843989 DOI: 10.1371/journal.pone.0067140] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
10 Piccoli GB, Grassi G, Cabiddu G, Nazha M, Roggero S, Capizzi I, De Pascale A, Priola AM, Di Vico C, Maxia S, Loi V, Asunis AM, Pani A, Veltri A. Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease. Rev Diabet Stud. 2015;12:87-109. [PMID: 26676663 DOI: 10.1900/rds.2015.12.87] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
11 Smith EMD, Yin P, Jorgensen AL, Beresford MW; UK JSLE Study Group. Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study. Pediatr Rheumatol Online J 2018;16:14. [PMID: 29467038 DOI: 10.1186/s12969-018-0230-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Schmieder RE. Renin inhibitors: optimal strategy for renal protection. Curr Hypertens Rep 2007;9:415-21. [PMID: 18177590 DOI: 10.1007/s11906-007-0076-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Lakkis JI, Weir MR. Hyperkalemia in the Hypertensive Patient. Curr Cardiol Rep 2018;20:12. [PMID: 29492706 DOI: 10.1007/s11886-018-0954-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC;  HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-138. [PMID: 25234519 DOI: 10.1093/cid/ciu617] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 24.7] [Reference Citation Analysis]
15 Lopez-Jaramillo P, Lopez-Lopez J, Lopez-Lopez C, Rodriguez-Alvarez MI. The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetol Metab Syndr 2014;6:31. [PMID: 24594121 DOI: 10.1186/1758-5996-6-31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
16 Alvarado M, Schaubel DE, Reddy KR, Bittermann T. Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation. Liver Transpl 2021;27:1154-64. [PMID: 33733570 DOI: 10.1002/lt.26054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wu B, Zhang S, Lin H, Mou S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis. J Diabetes Investig 2018;9:152-61. [PMID: 28296280 DOI: 10.1111/jdi.12653] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Walsh M. SONAR: Do a New Design and Statistically Significant Results Translate to Reliability? Clin J Am Soc Nephrol 2020;15:889-91. [PMID: 32019759 DOI: 10.2215/CJN.08540719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chan KW, Lee PW, Leung CP, Law YK, Gao L, Chan GC, Yiu WH, Lam TP, Tang SC. PRAgmatic Clinical Trial Design of Integrative MediCinE (PRACTICE): A Focus Group Series and Systematic Review on Trials of Diabetes and Kidney Disease. Front Med (Lausanne) 2021;8:668913. [PMID: 34513860 DOI: 10.3389/fmed.2021.668913] [Reference Citation Analysis]
20 Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 2019;32:499-516. [PMID: 31119681 DOI: 10.1007/s40620-019-00617-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
21 Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013;347:f6008. [PMID: 24157497 DOI: 10.1136/bmj.f6008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 116] [Article Influence: 16.3] [Reference Citation Analysis]
22 Gaudreault-Tremblay MM, Foster BJ. Benefits of Continuing RAAS Inhibitors in Advanced CKD. Clin J Am Soc Nephrol 2020;15:592-3. [PMID: 32253276 DOI: 10.2215/CJN.02920320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mohd-Tahir NA, Li SC. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. PLoS One 2019;14:e0212832. [PMID: 30817790 DOI: 10.1371/journal.pone.0212832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Cheungpasitporn W, Thongprayoon C, Mao MA, Kittanamongkolchai W, Sathick IJ, Erickson SB. The Effect of Renin-angiotensin System Inhibitors on Kidney Allograft Survival: A Systematic Review and Meta-analysis. N Am J Med Sci 2016;8:291-6. [PMID: 27583237 DOI: 10.4103/1947-2714.187141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
25 Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifirò G. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci 2021;22:4824. [PMID: 34062938 DOI: 10.3390/ijms22094824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Elley CR, Robinson T, Moyes SA, Kenealy T, Collins J, Robinson E, Orr-Walker B, Drury PL. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care 2013;36:3113-20. [PMID: 23801726 DOI: 10.2337/dc13-0190] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
27 Badve SV, Brown F, Hawley CM, Johnson DW, Kanellis J, Rangan GK, Perkovic V. Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol. 2011;7:295-300. [PMID: 21321568 DOI: 10.1038/nrneph.2010.186] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
28 Mengual L, Roura P, Serra M, Montasell M, Prieto G, Bonet S. Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. Cardiovasc Diabetol 2010;9:14. [PMID: 20350315 DOI: 10.1186/1475-2840-9-14] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
29 Adarkwah CC, Gandjour A, Akkerman M, Evers SM. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model. PLoS One 2011;6:e26139. [PMID: 22022539 DOI: 10.1371/journal.pone.0026139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
30 Harasemiw O, Drummond N, Singer A, Bello A, Komenda P, Rigatto C, Lerner J, Sparkes D, Ferguson TW, Tangri N. Integrating Risk-Based Care for Patients With Chronic Kidney Disease in the Community: Study Protocol for a Cluster Randomized Trial. Can J Kidney Health Dis 2019;6:2054358119841611. [PMID: 31191908 DOI: 10.1177/2054358119841611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, Baigent C, Chalmers J, Li N, Woodward M, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680. [PMID: 24092942 DOI: 10.1136/bmj.f5680] [Cited by in Crossref: 142] [Cited by in F6Publishing: 129] [Article Influence: 17.8] [Reference Citation Analysis]
32 Oliva-Damaso N, Mora-Gutiérrez JM, Bomback AS. Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management. J Clin Med 2021;10:1855. [PMID: 33923227 DOI: 10.3390/jcm10091855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Debnath S, Thameem F, Alves T, Nolen J, Al-Shahrouri H, Bansal S, Abboud HE, Fanti P. Diabetic nephropathy among Mexican Americans. Clin Nephrol 2012;77:332-44. [PMID: 22445478 DOI: 10.5414/cn107487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, Cleland JG, Khwaja A, El Nahas M. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 2016;31:255-61. [PMID: 26429974 DOI: 10.1093/ndt/gfv346] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
35 Taal MW. Screening for chronic kidney disease: preventing harm or harming the healthy? PLoS Med 2012;9:e1001345. [PMID: 23185137 DOI: 10.1371/journal.pmed.1001345] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
36 Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570. [PMID: 18385424 DOI: 10.1681/asn.2007101155] [Cited by in Crossref: 122] [Cited by in F6Publishing: 51] [Article Influence: 9.4] [Reference Citation Analysis]
37 Williams ME. The goal of blood pressure control for prevention of early diabetic microvascular complications. Curr Diab Rep 2011;11:323-9. [PMID: 21526351 DOI: 10.1007/s11892-011-0193-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
38 Kim DH, Rich MW. Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. Can J Cardiol 2016;32:1097-107. [PMID: 27378591 DOI: 10.1016/j.cjca.2016.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
39 Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010;53:49-57. [PMID: 19876613 DOI: 10.1007/s00125-009-1577-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
40 Tang WH, Lin FH, Lee CH, Kuo FC, Hsieh CH, Hsiao FC, Hung YJ. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014;45:293-301. [PMID: 23775007 DOI: 10.1007/s12020-013-0002-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
41 Schmieder RE, Martin S, Lang GE, Bramlage P, Böhm M. Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Dtsch Arztebl Int 2009;106:556-62. [PMID: 19795011 DOI: 10.3238/arztebl.2009.0556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
42 Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2020;10:CD007004. [PMID: 33107592 DOI: 10.1002/14651858.CD007004.pub4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
43 Shen J, Huang YM, Song XN, Hong XZ, Wang M, Ling W, Zhang XX, Zhao HL. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin Angiotensin Aldosterone Syst 2016;17:1470320316656481. [PMID: 27377659 DOI: 10.1177/1470320316656481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
44 Ren W, Zhao C, Wang Y, Fang Y, Huang Z, Chen W, Wang L, Hu W, Wang K, Ni L. Ramipril can alleviate the accumulation of renal mesangial matrix in rats with diabetic nephropathy by inhibiting insulin-like growth factor-1. Acta Cir Bras 2019;34:e20190010000007. [PMID: 30785508 DOI: 10.1590/s0102-865020190010000007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Wu MH, Lin CN, Chiu DT, Chen ST. Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease. Diagnostics (Basel) 2020;10:E207. [PMID: 32283658 DOI: 10.3390/diagnostics10040207] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid Med Cell Longev 2014;2014:752387. [PMID: 25180070 DOI: 10.1155/2014/752387] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
47 Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542-51. [PMID: 19261819 DOI: 10.2215/CJN.04750908] [Cited by in Crossref: 178] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
48 Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009;:CD003598. [PMID: 19588343 DOI: 10.1002/14651858.CD003598.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]